Table 1.

Quantified antibodies of patients on hemodialysis throughout 24 weeks after the first vaccination.

Variable	All	Non-Responder	Insufficient Responder	Responder	Subgroup Comparison	Correlation with Anti -SARS-CoV-2 IgG 24 Weeks after 1st Vac
	MD [Q1;Q3], (Range: Min–Max) or n (% of Subgroup)
Patients	59	12	28	19	NA	NA
SARS-CoV-2 IgG against the nucleocapsid protein, S/CO ratio
24 weeks after 1st vac	0.05 [0.03; 0.10],	0.07 [0.04; 0.11],	0.05 [0.04; 0.15],	0.04 [0.04; 0.06],	p = 0.463 *	−0.175; p = 0.194 †
	(0.02–0.47)	(0.02–0.17)	(0.02–0.47)	(0.03–0.23)
SARS-CoV-2 IgG against the spike protein, BAU/mL
before 1st vac	5 [5; 5],	5 [5; 5],	5 [5; 5],	5 [5; 5],	p = 0.844 *	0.089; p = 0.506 †
	(5–22)	(5–6)	(5–12.5)	(5–22)
6 weeks after 1st vac	918 [322; 1505],	172 [58; 586],	823 [364; 1127],	1794 [1222; 2080],	p < 0.001 *	0.669; p < 0.001 †
	(5–2080)	(5–871)	(132–1672)	(117–2080)
12 weeks after 1st vac	298 [111; 605],	44 [5; 85],	265 [175; 414],	723 [497; 1275],	p < 0.001 *	0.918; p < 0.001 †
	(5–2080)	(5–132)	(54–1040)	(130–2080)
24 weeks after 1st vac	89 [38; 224],	13 [5; 23],	78 [57; 172],	292 [183; 482],	p < 0.001 *	NA
	(5–1150)	(5–30)	(34–362)	(82–1150)

Non-responder = anti-SARS-CoV-2 IgG < 33.8 BAU/mL and neutralizing antibody titer < 1:20; insufficient responder = anti-SARS-CoV-2 IgG ≥ 33.8 BAU/mL but neutralizing antibody titer efficacy < 1:20; responder = anti-SARS-CoV-2 IgG ≥ 33.8 BAU/mL and neutralizing antibody titer ≥ 1:20; vac = vaccination; MD = median; Q1 = 1st quartile; Q3 = 3rd quartile; n = count; NA = not applicable; * = Kruskal–Wallis test. ^† = Spearman’s correlation coefficient.